← Back to Search

Nonsteroidal Anti-inflammatory Drug

50 mg daily oral dose for Progressive Supranuclear Palsy

Phase 1 & 2
Waitlist Available
Research Sponsored by NeuroTau, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12-weeks
Awards & highlights

Study Summary

This trial is testing a new drug to see if it can improve symptoms of Progressive Supranuclear Palsy, compared to a fake drug.

Eligible Conditions
  • Progressive Supranuclear Palsy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12-weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12-weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Heartburn
Secondary outcome measures
CSF biomarker change from baseline
Pharmacodynamic parameter of NFL
Pharmacodynamic parameter of amyloid beta peptide
+4 more
Other outcome measures
Clinical Global Impression of Disease Severity (CGI-ds)
Clinical global Impression of Change
Color Trails Test
+7 more

Trial Design

6Treatment groups
Active Control
Placebo Group
Group I: 50 mg daily oral doseActive Control1 Intervention
50 mg daily, oral dose of tolfenamic acid
Group II: 300 mg daily oral doseActive Control1 Intervention
300 mg daily, oral dose of tolfenamic acid
Group III: 600 mg daily oral doseActive Control1 Intervention
50 mg daily, oral dose of tolfenamic acid
Group IV: Placebo control - 50 mg daily oral dosePlacebo Group1 Intervention
50 mg daily oral placebo control
Group V: Placebo control - 300 mg daily oral dosePlacebo Group1 Intervention
300 mg daily oral placebo control
Group VI: Placebo control - 600 mg daily oral dosePlacebo Group1 Intervention
600 mg daily oral placebo control

Find a Location

Who is running the clinical trial?

NeuroTau, Inc.Lead Sponsor
The Cleveland ClinicOTHER
1,028 Previous Clinical Trials
1,364,454 Total Patients Enrolled
Nasser Zawia, PhDStudy DirectorNeuroTau, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Would it be possible to join the trial if one were over 40 years old?

"The required age range for this clinical trial is between 40-85 years old."

Answered by AI

Are we still looking for participants in this experiment?

"Unfortunately, this particular clinical trial is no longer recruiting patients. Although the last update was on 1/31/2020, the study was initially posted over a year ago on 1/1/2021. There are 20 other trials that are still looking for participants."

Answered by AI

Are there any other examples of 600 mg oral doses in clinical trials?

"There is one active study involving a 600 mg daily oral dose, with zero Phase 3 trials. Most of the clinical research for a 600 mg daily oral dose is based in Las Vegas, but there is one other location conducting these tests."

Answered by AI

To whom does this clinical opportunity extend?

"In this clinical trial, we are looking for 24 participants who meet the following criteria: -Aged 40 to 85 years old -Have supranuclear palsy, progressive -Modified Hachinski score ≤ 3 -Score ≥ 15 on the Mini-Mental State Examination (MMSE) at screening -At least a 12-month history of postural instability or falls during the first 3 years that symptoms are present -An akinetic-rigid syndrome with prominent axial rigidity"

Answered by AI

How many individuals are being given the chance to participate in this research project?

"Unfortunately, this particular study is no longer enrolling patients. It was originally posted on January 1st 2021 but the most recent edit was done on January 31st 2020. If you're looking for other studies, there are 19 ongoing trials for supranuclear palsy, progressive and 1 trial involving a 600 mg oral dose that are still admitting patients."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks
Zoltan Mari, MD 2021. "Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04253132.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top